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Abstract
Background: Recently, serum 25-hydroxyvitamin D (25OHD) levels were shown to be associated with the survival of 
patients with colorectal cancer. However, 25OHD levels were measured a median of 6 years before diagnosis or were 
predicted levels. In this study, we directly measured serum 25OHD levels at surgery and examined the association with 
survival among patients with colorectal cancer.
Methods: We started a prospective cohort study to find prognostic factors in patients with colorectal cancer from 
2003 to 2008 and stored serum samples and clinical data. As part of a post-hoc analysis, serum 25OHD levels were 
measured by radioimmunoassay. Association between overall survival and serum 25OHD levels were computed using 
the Cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer 
stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of 
lymph nodes with metastasis at surgery. Unadjusted and adjusted hazard ratios (HR) and 95% confidence intervals 
(95% CI) were determined.
Results: Serum 25OHD levels were measured in 257 patients. Only 3% had sufficient levels (30 ng/ml and greater). 
Based on month of blood sampling, an annual oscillation of 25OHD levels was seen, with levels being lower in spring 
and higher in late summer. Higher 25OHD levels were associated with better overall survival under multi-variate 
analysis (HR, 0.91: 95% CI, 0.84 to 0.99, P = 0.027).
Conclusions: These results suggest that higher 25OHD levels at surgery may be associated with a better survival rate 
of patients with colorectal cancer.
Background
Sunlight exposure has been suggested to reduce cancer
risk [1]. In addition, living at higher latitudes with lower
sunlight exposure is positively associated with cancer
mortality [2]. Because vitamin D is made under the skin
by exposure to ultraviolet-B radiation in sunlight, low lev-
els of serum vitamin D may contribute to a higher risk of
morbidity and mortality associated with colon cancer [3].
One plausible explanation for why increased sun expo-
sure and higher circulating levels of vitamin D are associ-
ated with a decreased risk of deadly cancers is that
epithelial cells convert the primary circulating form of
vitamin D, 25-hydroxyvitamin D (25OHD), to its active
form, 1,25-dihydoroxyvitamin D, inside the cells; this
active form binds to vitamin D receptors in the nucleus to
regulate a variety of genes [4]. These genes help prevent
malignant transformation by keeping cellular prolifera-
tion and differentiation within normal ranges. In turn, if a
cell becomes malignant, 1,25-dihydroxyvitamin D can
induce apoptosis and prevent angiogenesis, thereby
reducing the potential for the malignant cell to survive.
Two meta-analyses showed that vitamin D deficiency is
a risk factor for the development of colorectal cancer
[5,6]. Sporadic colon cancer has been induced by a west-
ern diet in a mouse model, and was prevented by increas-
ing dietary calcium and vitamin D levels [7]. A pilot
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Page 2 of 8randomized, double-blind, placebo-controlled clinical
trial showed that vitamin D reduced cell proliferation and
increased BCL2-associated X protein, an apoptosis pro-
moter, in colorectal mucosa [8-10]. High doses (1,100 IU)
of vitamin D plus calcium were shown to significantly
reduce cancer incidence in women [11], although low
doses (400 IU) of vitamin D did not decrease the inci-
dence of colorectal cancer [12]. Recently, Ng et al. dem-
onstrated that higher pre-diagnosis blood 25OHD levels
were associated with a significant improvement in overall
survival of patients with colorectal cancer [13]. However,
they only had a single measurement of plasma 25OHD
levels taken a median of 6 years before diagnosis. Next,
they calculated post-diagnosis 25OHD levels using race,
geographic region, and baseline values of physical activ-
ity, body mass index, and vitamin D intake reported 1 to 4
years after colorectal cancer diagnosis according to Gio-
vannucci's method [14]. Using these predicted 25OHD
levels, they demonstrated that higher 25OHD levels after
diagnosis of colorectal cancer may be associated with
improved survival [15]. For a more accurate portrayal of
25OHD levels, we collected blood samples at surgery,
measured 25OHD levels directly, and investigated the
relationship between individual serum levels of 25OHD
and overall survival in patients diagnosed with colorectal
cancer, according to the vitamin D hypothesis [3].
Methods
Informed consent
This study was designed as post-hoc analysis of a pro-
spective cohort study to find prognostic markers in the
serum of patients with colorectal cancer from May 2003
to January 2008 and approved by the Ethics Committee
for Biomedical Research of the Jikei Institutional Review
Board, Jikei University School of Medicine, Tokyo, Japan.
All patients provided written informed consent.
Study Population
Peripheral blood samples were obtained from colorectal
cancer patients who underwent surgery at the Depart-
ment of Surgery, Jikei University Hospital. Patients who
were treated with chemotherapy and/or radiation before
surgery to reduce the size of the tumor were excluded.
Two hundred and fifty-seven patients were included in
this study. Prognostic factors known to influence colorec-
tal cancer mortality were extracted from the medical
record, including age at surgery, tumor stage, primary
tumor location, and year of diagnosis. According to the
tumor-node-metastasis system of the American Joint
Committee on Cancer [16], stages (I, II, III and IV) were
determined based on pathologic analysis of the surgical
specimens [17]. Residual tumor after surgery was classi-
fied into three categories: R0, no residual tumor; R1,
microscopic residual tumor; and R2, macroscopic resid-
ual tumor [18]. Metastases to lymph nodes resected at
surgery were pathologically examined and counted. All
patients were periodically (every 0.5 to 2 months) exam-
ined on an outpatient basis to make sure they had not
relapsed. Examinations consisted of standard tests,
including colonoscopy and computed tomography.
Patients were followed until July 31, 2009, or death,
whichever came first. Because serum 25OHD levels were
higher in the first half of the study span, the time period
of surgery was divided into two groups (between May
2003 and December 2005 and between January 2006 and
January 2008) and was used as one of the covariates.
Samples and 25OHD measures
Pathological stages and number of lymph nodes with
metastasis were determined the same day or the next day
after surgery. In each case, serum samples were obtained
in the peri-operative period and stored at -80°C until
25OHD was measured. Serum 25OHD levels were mea-
sured twice by radioimmunoassay at SRL Inc. (Hachioji,
Tokyo, Japan), as described previously [19,20]. When
duplicated data differed by 5 ng/mL or more, measures
were repeated, although this occurred in only 7 cases.
Personnel who measured 25OHD levels were blinded to
clinical information.
Endpoints
Because some patients could not obtain complete remis-
sion after surgery, death was used as the primary end-
point in all patients, and relapse was used as the
secondary endpoint in patients who could obtain com-
plete resection after surgery.
Statistical analysis
Analysis of variance and chi-square test were used to
evaluate differences in patient characteristics between
25OHD levels, which were divided into quartiles (3-7 ng/
mL, 8-10 ng/mL, 11-15 ng/mL, and 16-36 ng/mL). Over-
all survival, cancer-specific survival, and disease-free sur-
vival curves were compared with the serum 25OHD
levels using Cox proportional hazard models with or
without multivariate analysis using age at diagnosis (years
old), gender, calendar month of blood sampling, cancer
stage (I, II, III, and IV), residual tumor (R0, R1, and R2),
number of lymph nodes with metastasis, and time period
of surgery (between May 2003 and December 2005 and
between January 2006 and January 2008). Adjusted haz-
ard ratios (HR) and 95% confidence intervals (CI) were
computed. All statistical analyses were performed using
STATA 9.1 (STATA Corp., College Station, TX). P < 0.05
was considered statistically significant.
Results
Serum 25OHD levels
Serum 25OHD levels were measured in 257 patients (Fig.
1). Most patients (85%) showed insufficient levels (less
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Page 3 of 8than 20 ng/mL) of 25OHD; only 3% had sufficient levels
(30 ng/ml and greater). Quartile points of distribution
were as follows: 25%, 7 ng/mL; 50%, 10 ng/mL; and 75%,
15 ng/mL.
Levels of 25OHD were compared based on month of
blood sampling (Fig. 2). There was an annual oscillation
in 25OHD levels, which were lower in spring and higher
in late summer. Compared with December, 25OHD levels
were significantly lower in March (P = 0.002) and May (P
= 0.001) and significantly higher in September (P =
0.025).
Patients' characteristics according to quartiles of
25OHD levels are shown in Table 1. There were no signif-
icant differences in quartiles between age at surgery, gen-
der, cancer stage, location of the tumor, and number of
lymph nodes with metastasis. On the other hand, an ear-
lier time period of surgery was associated with signifi-
cantly higher (P < 0.001) 25OHD levels than a later
surgical time period.
Overall survival and 25OHD
Among 257 patients with colorectal cancer, there were 39
deaths, 30 of which were colorectal cancer-specific
deaths. The median time of follow-up of participants still
alive at the end of the study was 32.4 months. We
assessed the influence of serum 25OHD levels on overall
survival of patients using the Cox proportional hazard
model adjusted for age at diagnosis (years old), gender,
calendar month of blood sampling, cancer stage (I, II, III,
and IV), assessment of residual tumor after surgery (R0,
R1, and R2), period of surgery, and number of lymph
nodes with metastasis (Table 2). Higher serum 25OHD
levels were associated with a significant reduction in the
risk of overall survival with adjustment for age at diagno-
sis, gender, calendar month of blood sampling, cancer
stage, residual tumor after surgery, time period of sur-
gery, location of tumor, adjuvant chemotherapy, and
number of lymph nodes with metastasis (HR, 0.91:
95%CI, 0.84 to 0.99, P = 0.027). When we divided 25OHD
into quartiles and computed overall survival using the
Cox proportional hazard model, the highest 25OHD
quartile was associated with a significant reduction in
death rate with adjustment for the same factors (HR, 0.16:
95% CI, 0.04 to 0.63, P = 0.009) (Table 3). Without adjust-
ment, there was no association between 25OHD quartiles
and overall survival. There was no significant association
between 25OHD levels and colorectal cancer-specific
death (Table 4) or disease-free survival (Table 5).
Discussion
In this study, the median serum 25OHD levels in patients
with colorectal cancer was 10 ng/mL, and 87% were in a
vitamin D-insufficient state (less than 30 ng/mL), which
is lower than expected. SRL Inc. measured 25OHD,
which has a range of 7 ng/mL to 41 ng/mL as determined
by data from healthy volunteers [19]. When data from the
US National Health and Nutrition Examination Survey
(NHANES) 2001-2004 were compared with data from
1988-1994, the prevalence of 25OHD levels less than 10
ng/mL increased from 2% to 6% in total and 9% to 29% in
non-Hispanic blacks, with a corresponding decrease in
the prevalence of levels of 30 ng/mL or more from 45% to
23% and 12% to 3%, respectively [21]. The population of
this study was Japanese, and the average skin color was
between that of white and black subjects. The study
period was between 2003 and 2008, which, although
partly overlapping the later period of NHANES 2001-
2004, was conducted mostly after that study. Moreover,
populations who develop colorectal cancer tend to have
lower serum 25OHD levels [5,6]. Thus, a higher preva-
lence of 25OHD insufficiency in Japanese patients with
colorectal cancer after 2003 may be plausible, although
we do not have exact controls to verify this hypothesis.
Figure 2 Serum 25OHD levels in each calendar month. All points 
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Page 4 of 8Levels of 25OHD oscillated with the seasons, showing
lower levels in spring and higher levels in late summer.
This finding was similar to that reported in a British
study [22]. In an ecological study, the survival of colon
cancer patients in Norway was highest for those diag-
nosed in the summer and autumn [23]. These findings are
consistent with our results.
Among 257 Japanese patients with colorectal cancer,
higher 25OHD levels were associated with a significantly
better overall survival under Cox proportional hazard
models with multi-variate adjustment for month of
serum sampling as well as age at diagnosis, gender, cancer
stage, residual tumor after surgery, time period of sur-
gery, and number of lymph nodes with metastasis at sur-
gery, which is consistent with previous studies [14,15].
However, without adjustment, there was no association
between 25OHD levels and overall survival. There was no
significant association between 25OHD levels and col-
orectal cancer-specific deaths or disease-free survival. A
meta-analysis showed that vitamin D supplements may
improve overall survival [24] as well as cardiovascular
mortality [25]. Thus, patients with higher vitamin D lev-
els may have an advantage in both cancer- and non-can-
cer-related deaths, leading to an increase in overall
survival rather than disease-free survival.
In patients with early-stage non-small-cell lung cancer
[26] or breast cancer [27], higher 25OHD levels were
reported to be associated with better prognosis. In con-
trast, Freedman et al. examined 536 cancer deaths in
146,578 person-years, and found an inverse relationship
between 25OHD levels and colorectal cancer mortality,
but not other types of cancers [28]. A positive association
between serum 25OHD levels and survival may be
observed in colorectal cancer, but is still controversial in
other types of cancers.
This study has several limitations. Our study popula-
tion was not large enough to detect minor differences in
25OHD levels. Moreover, our findings could be limited
Table 1: Patient characteristics according to quartile of serum 25OHD (n = 257)
Quartile 1 (3-7 
ng/mL) n = 71
Quartile 2 (8-10 
ng/mL) n = 58
Quartile 3 (11-15 
ng/mL) n = 65
Quartile 4 (16-36 
ng/mL) n = 63
P value
Serum 25OHD, ng/mL, mean 
± SD
5.2 ± 1.7 9.0 ± 0.8 12.6 ± 1.4 21.9 ± 5.2
Age at surgery, years 64 ± 15 66 ± 13 65 ± 12 65 ± 10 0.76*1
Gender, % female 41 43 34 26 0.18*2
Stage, % 0.78*2
Stage I 21 17 18 24
Stage II 23 31 37 22
Stage III 35 32 31 35
Stage IV 21 20 14 19
Location of tumor,% 0.24*2
Proximal colon 38 44 40 27
Distal colon 32 19 18 23
Rectum 30 37 42 50
Type of resection, % 0.84*2
R0 76 79 82 81
R1 9 10 8 4
R2 15 11 10 15
Number of lymph nodes 
with metastasis
2.2 ± 4.0 3.0 ± 6.8 2.2 ± 4.0 1.6 ± 3.0 0.87*3
Time period of surgery < 0.001*2
May 2003 - December 2005 27 43 55 65
January 2006 - January 2008 73 57 45 35
*1: P value was calculated using one-way analysis of variance.
*2: P value was calculated using chi-square test.
*3: P value was calculated using Kruskal-Wallis rank test.
R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor.
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Table 2: Cox proportional hazard models of overall survival without or with multivariate adjustment*1
Variable Single-variate analyses Multivariate analysis
Crude HR 95% CI P value AHR 95% CI P value
25OHD, ng/mL 0.98 0.93-1.02 0.31 0.91 0.84-0.99 0.027
Age at surgery, years 1.01 0.98-1.04 0.49 1.07 1.03-1.12 0.002
Gender, female 1.26 0.66-2.41 0.49 1.59 0.49-5.15 0.44
Time period of surgery
May 2003 - December 2005 0.94 0.48-1.85 0.87 0.41 0.13-1.27 0.12
January 2006 - January 2008 reference
Stage
Stage I 0.00 - - 0.00 - -
Stage II 0.02 0.01-4.32 < 0.001 0.02 0.02-1.74 0.13
Stage III 0.13 0.07-0.27 < 0.001 1.13 0.16-7.85 0.90
Stage IV Reference Reference
Location of tumor
Proximal colon 1.07 0.52-2.22 0.86 1.42 0.55-3.68 0.47
Distal colon 0.45 0.15-1.34 0.15 0.42 0.09-1.94 0.27
Rectum Reference Reference
Type of resection, %
R0 0.04 0.02-0.09 < 0.001 0.01 0.00-0.11 < 0.001
R1 1.04 0.48-2.26 0.92 0.44 0.11-1.78 0.25
R2 Reference Reference
Adjuvant chemotherapy 6.06 2.15-17.10 0.001 0.75 0.17-3.34 0.71
Number of lymph nodes with metastasis*2 1.08 1.05-1.11 < 0.001 1.09 1.02-1.16 0.016
*1: Multivariate hazard ratios (HR), 95% confidence intervals (CI), and P values were adjusted for age at diagnosis (years), gender, calendar 
month of blood sampling, cancer stage (I, II, III, and IV), residual tumor after surgery (R0, no residual tumor; R1, microscopic residual tumor; R2, 
macroscopic residual tumor), time period of surgery (between May 2003 and December 2005 or between January 2006 and January 2008), 
location of tumor, adjuvant chemotherapy, and number of lymph nodes with metastasis.
*2: Lymph nodes were resected at surgery, and metastases in lymph nodes were confirmed pathologically.
Table 3: Cox proportional hazard models with multivariate adjustment*1
Covariate Hazard Ratio P value 95% Confidence Interval
25OHD, ng/mL
3-7 (Quartile 1) 0.50 0.22 0.16-1.54
8-10 (Quartile 2) 0.55 0.29 0.18-1.65
11-15 (Quartile 3) Reference
16-36 (Quartile 4) 0.16 0.009 0.04-0.63
*1: Multivariate hazard ratios, 95% confidence intervals, and P values were adjusted for age at diagnosis (years), gender, calendar month of 
blood sampling, cancer stage (I, II, III, and IV), residual tumor after surgery (R0, no residual tumor; R1, microscopic residual tumor; R2, 
macroscopic residual tumor), time period of surgery (between 2003 and 2005 or between 2006 and 2008), and number of lymph nodes with 
metastasis.
*2: Lymph nodes were resected at surgery and metastases in lymph nodes were confirmed pathologically.
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gery and not at diagnosis; it is possible that samples taken
at the time of diagnosis may have led to different results,
because lifestyle factors, including outdoor activities and
body mass index which are strongly associated with
25OHD levels might change in patients, when they are
told they have colorectal cancer. However, because we did
not include patients treated with chemotherapy and/or
radiotherapy before surgery, we felt that changes in
serum 25OHD levels from diagnosis to time of surgery
would not be big. In addition, after surgery, 25OHD levels
may change because of changes in physical activity, body
mass index, and diet. However, because we only took
blood samples at the time of surgery, we could not exam-
ine these potential effects. Moreover, we did not measure
possible confounders such as physical activity and body
mass index. In addition, because this was an observa-
tional study, treatment including adjuvant chemotherapy
was not standardized, as it would have been in a clinical
trial setting. Thus, the choice of therapy could also have
an effect on the overall survival. Jikei University Hospital
is a private hospital, and most patients were thought to
live in Tokyo and the surrounding prefectures. Thus, our
results could also have been confounded by socioeco-
nomic factors. For example, patients living in Tokyo area
may have higher opportunity to be diagnosed with col-
orectal cancer at an earlier stage because they are more
likely to undergo screening tests or a medical check up,
which can be associated with better survival. On the
other hand, they may spend more time indoors, which
could help explain why serum 25OHD levels were low.
Recently, single nuclear polymorphisms of the vitamin D
receptor were reported to strongly affect survival among
patients with non-small-cell lung cancer [29]. Synergistic
effects of single nuclear polymorphisms of vitamin D
receptor and 25OHD on survival should be prospectively
Table 4: Cox proportional hazard models of cancer death without or with multivariate adjustment*1
Variable Single-variate analyses Multivariate analysis
Crude HR 95% CI P value AHR 95% CI P value
25OHD, ng/mL 0.99 0.94-1.05 0.75 0.98 0.89-1.08 0.67
Age at surgery, years 0.98 0.96-1.01 0.26 1.02 0.96-1.08 0.57
Gender, female 1.36 0.65-2.85 0.41 1.14 0.24-5.34 0.87
Time period of surgery
May 2003 - December 2005 1.45 0.67-3.13 0.87 1.32 0.28-6.19 0.73
January 2006 - January 2008 reference
Stage
Stage I 0.00 - - 0.00 - -
Stage II 0.00 - < 0.001 0.00 - -
Stage III 0.01 0.04-0.20 < 0.001 0.49 0.02-10.28 0.65
Stage IV Reference Reference
Location of tumor
Proximal colon 0.77 0.31-1.88 0.56 0.66 0.17-2.56 0.54
Distal colon 0.56 0.18-1.74 0.32 0.36 0.05-2.44 0.30
Rectum Reference Reference
Type of resection, %
R0 0.03 0.01-0.07 < 0.001 0.02 0.00-0.75 0.034
R1 0.94 0.40-2.18 0.88 0.51 0.07-3.52 0.49
R2 Reference Reference
Adjuvant chemotherapy 6.24 1.89-20.62 0.003 0.65 0.09-4.85 0.67
Number of lymph nodes with metastasis*2 1.08 1.05-1.12 < 0.001 1.13 1.04-1.23 0.003
*1: Multivariate hazard ratios (HR), 95% confidence intervals (CI), and P values were adjusted for age at diagnosis (years), gender, calendar month 
of blood sampling, cancer stage (I, II, III, and IV), residual tumor after surgery (R0, no residual tumor; R1, microscopic residual tumor; R2, 
macroscopic residual tumor), time period of surgery (between May 2003 and December 2005 or between January 2006 and January 2008), 
location of tumor, adjuvant chemotherapy, and number of lymph nodes with metastasis.
*2: Lymph nodes were resected at surgery, and metastases in lymph nodes were confirmed pathologically.
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doses of vitamin D supplements are warranted to deter-
mine if vitamin D truly improves survival of patients with
colorectal cancer.
Conclusions
These results suggest that higher 25OHD levels at sur-
gery may be associated with a better survival rate of
patients with colorectal cancer.
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